FY2025 EPS Estimates for Hologic Decreased by Zacks Research

Hologic, Inc. (NASDAQ:HOLX) – Investment analysts at Zacks Research reduced their FY2025 earnings per share (EPS) estimates for Hologic in a note issued to investors on Wednesday, March 19th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will earn $4.25 per share for the year, down from their previous forecast of $4.26. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s Q2 2026 earnings at $1.10 EPS, Q3 2026 earnings at $1.14 EPS and FY2026 earnings at $4.59 EPS.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%.

A number of other equities research analysts also recently weighed in on HOLX. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Royal Bank of Canada reduced their target price on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th. Argus downgraded Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Wolfe Research started coverage on Hologic in a research report on Friday, December 13th. They issued a “peer perform” rating on the stock. Finally, BNP Paribas raised Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $84.62.

Hologic Price Performance

Hologic stock opened at $61.47 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. Hologic has a one year low of $60.34 and a one year high of $84.67. The firm has a market capitalization of $13.79 billion, a P/E ratio of 19.39, a PEG ratio of 2.14 and a beta of 0.97. The business has a fifty day moving average price of $66.06 and a 200-day moving average price of $73.99.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Swedbank AB grew its stake in Hologic by 18.8% during the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after acquiring an additional 306,562 shares in the last quarter. GSA Capital Partners LLP grew its stake in shares of Hologic by 22.2% in the 3rd quarter. GSA Capital Partners LLP now owns 5,762 shares of the medical equipment provider’s stock valued at $469,000 after buying an additional 1,048 shares during the period. OneDigital Investment Advisors LLC grew its stake in shares of Hologic by 5.4% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 7,075 shares of the medical equipment provider’s stock valued at $576,000 after buying an additional 360 shares during the period. Empowered Funds LLC grew its stake in shares of Hologic by 8.8% in the 3rd quarter. Empowered Funds LLC now owns 3,603 shares of the medical equipment provider’s stock valued at $294,000 after buying an additional 291 shares during the period. Finally, Pathstone Holdings LLC grew its stake in shares of Hologic by 7.7% in the 3rd quarter. Pathstone Holdings LLC now owns 29,731 shares of the medical equipment provider’s stock valued at $2,422,000 after buying an additional 2,121 shares during the period. 94.73% of the stock is currently owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.